PT1625210E
(pt)
|
2003-05-21 |
2011-03-15 |
Genzyme Corp |
Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
|
ES2400235T3
(es)
|
2006-04-28 |
2013-04-08 |
The Trustees Of The University Of Pennsylvania |
Método de producción escalable de AAV
|
EP4219547A3
(en)
*
|
2008-09-15 |
2023-10-18 |
uniQure biopharma B.V. |
Factor ix polypeptide mutant, its uses and a method for its production
|
CN105838737A
(zh)
*
|
2010-01-28 |
2016-08-10 |
费城儿童医院 |
用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
|
CA3182572A1
(en)
|
2013-04-17 |
2014-10-23 |
Genzyme Corporation |
Use of an il17 inhibitor for treating and preventing macular degeneration
|
AU2014354839B2
(en)
|
2013-11-26 |
2020-06-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors for treatment of glycogen storage disease
|
GB201401707D0
(en)
*
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
EP3102246B1
(en)
|
2014-02-06 |
2020-03-25 |
Genzyme Corporation |
Compositions and methods for treating and preventing macular degeneration
|
WO2015160977A1
(en)
*
|
2014-04-15 |
2015-10-22 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using smad3
|
HUE054768T2
(hu)
|
2014-05-02 |
2021-09-28 |
Genzyme Corp |
AAV vektorok retina és CNS génterápiára
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
US10526583B2
(en)
|
2014-07-02 |
2020-01-07 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for purifying recombinant adeno-associated virus
|
MX2017005834A
(es)
|
2014-11-05 |
2017-11-17 |
Voyager Therapeutics Inc |
Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
|
CN112375760A
(zh)
|
2014-11-14 |
2021-02-19 |
沃雅戈治疗公司 |
调节性多核苷酸
|
AU2015346162B2
(en)
|
2014-11-14 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
CN107636153B
(zh)
|
2014-12-23 |
2020-12-11 |
美国政府(由卫生和人类服务部的部长所代表) |
编码经修饰的g6pc的腺相关病毒载体及其用途
|
US10429288B2
(en)
|
2015-01-20 |
2019-10-01 |
Genzyme Corporation |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
SG10201907399RA
(en)
|
2015-02-10 |
2019-09-27 |
Genzyme Corp |
Enhanced delivery of viral particles to the striatum and cortex
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
CN115074366A
(zh)
|
2015-04-16 |
2022-09-20 |
埃默里大学 |
用于肝脏中蛋白质表达的重组启动子和载体及其用途
|
CA2983808C
(en)
|
2015-04-23 |
2022-03-22 |
Washington State University |
Smad7 gene delivery as a therapeutic
|
US11896651B2
(en)
|
2015-05-16 |
2024-02-13 |
Genzyme Corporation |
Gene editing of deep intronic mutations
|
US10954492B2
(en)
|
2015-06-10 |
2021-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
JP6854286B2
(ja)
|
2015-10-21 |
2021-04-07 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
コドン最適化された小型ATP7A cDNAおよび銅輸送障害を処置するための使用
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US11015174B2
(en)
*
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
EP3992283A1
(en)
*
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
RU2742612C2
(ru)
|
2015-12-15 |
2021-02-09 |
Джензим Корпорейшн |
Векторы на основе аденоассоциированного вируса для лечения муколипидоза типа ii
|
IL300254A
(en)
|
2016-02-05 |
2023-03-01 |
Univ Emory |
Administration of single-stranded or self-complementary adeno-associated virus 9 by injection into cerebrospinal fluid for the purposes of gene therapy in the central nervous system
|
JP6645279B2
(ja)
*
|
2016-03-11 |
2020-02-14 |
セイコーエプソン株式会社 |
撮影装置
|
US11702639B2
(en)
*
|
2016-03-31 |
2023-07-18 |
Spark Therapeutics, Inc. |
Column-based fully scalable rAAV manufacturing process
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR THE TREATMENT OF DISEASES
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
SG11201809699XA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
GB201612248D0
(en)
*
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
TN2019000047A1
(en)
|
2016-08-15 |
2020-07-15 |
Genzyme Corp |
Methods for detecting aav
|
JP2019530737A
(ja)
|
2016-08-23 |
2019-10-24 |
アコーオス インコーポレイテッド |
ヒト対象において非加齢性聴力障害を治療するための組成物および方法
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
PT3535388T
(pt)
|
2016-11-04 |
2023-06-27 |
Takeda Pharmaceuticals Co |
Métodos de purificação de vírus adeno-associados
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)治療組成物および方法
|
US11633504B2
(en)
|
2017-05-09 |
2023-04-25 |
Emory University |
Nucleic acids encoding clotting factor variants and their use
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
CN111032176A
(zh)
*
|
2017-06-30 |
2020-04-17 |
星火治疗有限公司 |
Aav载体柱纯化方法
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
KR20200044793A
(ko)
|
2017-08-03 |
2020-04-29 |
보이저 테라퓨틱스, 인크. |
Aav의 전달을 위한 조성물 및 방법
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
JP2021502060A
(ja)
|
2017-10-16 |
2021-01-28 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)の治療
|
WO2019169291A1
(en)
|
2018-03-02 |
2019-09-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
AU2019257755A1
(en)
|
2018-04-27 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of AADC viral vectors
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
CN113166208A
(zh)
|
2018-10-02 |
2021-07-23 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
JP2022504740A
(ja)
|
2018-10-12 |
2022-01-13 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によって重度のpkuを処置するための改善されたヒトpahの生成
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CN113302290A
(zh)
|
2018-11-16 |
2021-08-24 |
编码治疗公司 |
治疗威尔逊氏病的组合物和方法
|
DK3898981T3
(da)
|
2018-12-18 |
2024-01-22 |
Ultragenyx Pharmaceutical Inc |
Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme
|
CN113518628A
(zh)
|
2019-01-04 |
2021-10-19 |
阿尔特拉吉尼克斯制药公司 |
治疗威尔逊病的基因疗法构建体
|
AU2020208467A1
(en)
|
2019-01-18 |
2021-08-05 |
Voyager Therapeutics, Inc. |
Methods and systems for producing AAV particles
|
US20220243224A1
(en)
*
|
2019-04-15 |
2022-08-04 |
Children's Hospital Medical Center |
Viral vector manufacturing methods
|
WO2020216861A2
(en)
|
2019-04-23 |
2020-10-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New adeno-associated virus (aav) variants and uses thereof for gene therapy
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
US20220364114A1
(en)
|
2019-08-26 |
2022-11-17 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
AU2021208631A1
(en)
|
2020-01-17 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of CRX-autosomal dominant retinopathies
|
KR20220133941A
(ko)
|
2020-01-29 |
2022-10-05 |
젠자임 코포레이션 |
안과 유전자 치료를 위한 변형 아데노-관련 바이러스 캡시드 단백질 및 이의 사용 방법
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
AU2021225035A1
(en)
|
2020-02-21 |
2022-10-13 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
EP3868886A1
(en)
*
|
2020-02-21 |
2021-08-25 |
Bia Separations D.O.O. |
A method for separation or depletion of empty aav capsids from full aav capsids
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
WO2021230987A1
(en)
|
2020-05-13 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
US20220033782A1
(en)
*
|
2020-07-29 |
2022-02-03 |
Pall Corporation |
Adenovirus-associated viruses separation method
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
US20230294017A1
(en)
*
|
2020-08-18 |
2023-09-21 |
Sartorius Bia Separations D.O.O. |
Multimodal metal affinity processing aav capsids
|
SI3957378T1
(sl)
*
|
2020-08-18 |
2023-07-31 |
Sartorius BIA Separations D.O.O |
Večmodalna obdelava kapsid aav s kovinsko afiniteto
|
JPWO2022045055A1
(el)
*
|
2020-08-24 |
2022-03-03 |
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
AU2021355481A1
(en)
|
2020-10-01 |
2023-06-08 |
Genzyme Corporation |
Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
|
KR20230085170A
(ko)
|
2020-10-15 |
2023-06-13 |
에프. 호프만-라 로슈 아게 |
동시 유전자 활성화를 위한 핵산 구조체
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
AU2021372262A1
(en)
|
2020-11-02 |
2023-06-01 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
AU2021375404A1
(en)
|
2020-11-03 |
2023-06-08 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
US11821000B2
(en)
|
2020-11-10 |
2023-11-21 |
Dionex Corporation |
Method of separating viral vectors
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
CN117460832A
(zh)
|
2021-03-22 |
2024-01-26 |
建新公司 |
空aav衣壳和完整aav衣壳的尺寸排阻色谱分析
|
KR20240021231A
(ko)
*
|
2021-06-11 |
2024-02-16 |
스파크 테라퓨틱스, 인코포레이티드 |
Aav 벡터 컬럼 정제 방법
|
GB202110014D0
(en)
*
|
2021-07-12 |
2021-08-25 |
Cytiva Bioprocess R & D Ab |
A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
|
CA3226803A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Christian Fiedler |
Adeno-associated virus separation on a cation exchanger
|
WO2023034996A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034994A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034997A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
TW202334436A
(zh)
|
2021-11-02 |
2023-09-01 |
美商航海家醫療公司 |
Aav衣殼變異體及其用途
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023111580A1
(en)
|
2021-12-16 |
2023-06-22 |
University Of Dundee |
Targeted degradation of alpha-synuclein
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
TW202346599A
(zh)
|
2022-02-08 |
2023-12-01 |
美商航海家醫療公司 |
Aav衣殼變異體及其用途
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
WO2023174974A1
(en)
|
2022-03-18 |
2023-09-21 |
Merck Patent Gmbh |
Methods and compositions for purifying adeno associated virus particles
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023201272A1
(en)
|
2022-04-12 |
2023-10-19 |
Genzyme Corporation |
Use of irak4 modulators for gene therapy
|
US20230405014A1
(en)
|
2022-04-12 |
2023-12-21 |
Genzyme Corporation |
Use of an irak4 modulator for gene therapy
|
US20230407255A1
(en)
|
2022-04-12 |
2023-12-21 |
Genzyme Corporation |
Dendritic cell assay for innate immunogenicity to gene therapy agents
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023225481A1
(en)
|
2022-05-16 |
2023-11-23 |
Genzyme Corporation |
Methods of treating metachromatic leukodystrophy
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240062A1
(en)
|
2022-06-07 |
2023-12-14 |
Adverum Biotechnologies, Inc. |
Melanopsin variants for vision restoration
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|